Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.